

Allikad refluks

[i] Zhang Y. Epidemiology of esophageal cancer. *World Journal of Gastroenterology* : *WJG*. 2013;19(34):5598-5606.

[ii] Scott Merrell et al. pH-Regulated Gene Expression of the Gastric Pathogen *Helicobacter pylori*. *Infect Immun*. 2003; 71 (6): 3529-39.

[iii] Schlesinger PK et al. Limitations of 24-hour intraesophageal pH monitoring in the hospital setting. *Gastroenterology*. 1985; 89(4): 797-804.

[iv] Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. *Gastroenterology*. 2005; 128(3):771-8.

[v] Ardatskaia MD, Loginov VA, Minushkin ON. [Syndrome of bacterial overgrowth in patients with the reduced stomach acid secretion: some aspects of the diagnosis].

Eksp Klin Gastroenterol. 2014;(12):30-6.

[vi] Choung RS et al. Associations between medication use and functional gastrointestinal disorders: a population-based study. *Neurogastroenterol Motil*. 2013;25(5):413-9

[vii] Aseeri M et al. Gastric acid suppression by proton pump inhibitors as a risk factor for *Clostridium difficile*-associated diarrhea in hospitalized patients. *Am J Gastroenterol*. 2008;103(9):2308-13

[viii] Shikata T et al. Use of proton pump inhibitors is associated with anaemia in cardiovascular outpatients. *Circ J*. 2015;79(1):193-200

[ix] Lam JR et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. *JAMA*. 2013; 310(22):2435-42

[x] Hirschowitz BI, Worthington J and Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. *Aliment Pharmacol Ther*. 2008;27(11):1110-21

[xi] Henry EB et al. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. *Aliment Pharmacol Ther*. 2005;22(6):539-45

[xii] Ghebremariam YT et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. *Circulation*. 2013;128(8):845-53

[xiii] Charlot M et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. *Ann Intern Med*. 2010;153(6):378-86

[xiv] Haenisch B et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. *Eur Arch Psychiatry Clin Neurosci*. 2015; 265(5):419-28

[xv] Wijarnpreecha K et al. Proton pump inhibitors and risk of dementia. *Ann Transl Med*. 2016;4(12):240

[xvi] Jacob L, Hadji P and Kostev K. The use of proton pump inhibitors is positively associated with osteoporosis in postmenopausal women in Germany. *Cimacteric*. 2016;19(5):478-81

[xvii] Anderson BN, Johansen PB and Abrahamsen B. Proton pump inhibitors and osteoporosis. *Curr Opin Rheumatol*. 2016;28(4):420-5

[xviii] Richter JE. Advances in GERD. Current developments in the management of acid-related GI disorders. *Gastroenterol Hepatol (NY)*. 2009; 5(9): 613-615.

[xix] Kahrilas PJ, Gupta RR. *Gut*. 1990; 31 (1): 4-10

[xx] Austin GL, et al. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. *Dig Dis*

Sci. 2006;51(8):1307-12.

[xxi] *The Review of Natural Products by Facts and Comparisons*. 1999. St Louis: Wolters Kluwer Co.

[xxii] Mizuta et al. Effects of gamma oryzanol on gastric secretions in rats. *Folia Farmacol Japon*. 1978; 74: 285-95.

[xxiii] Ichimaru et al. Effects of gamma-oryzanol on gastric lesions and small intestinal propulsive activity. *Nihon Yakurigaku Zasshi*. 1984; 84 (6): 537-42.

[xxiv] *The Review of Natural Products by Facts and Comparisons*. 1999. St Louis: Wolters Kluwer Co.

[xxv] Khayyal. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. *Arzneimittelforschung*. 2001; 51 (7): 545-53.

[xxvi] Fukai et al. Anti-*Helicobacter pylori* flavonoids from licorice extract. *Life Sci*. 2002; 71 (12): 1449-63.

[xxvii] Wittschier et al. Aqueous extracts and polysaccharides from liquorice roots (*Glycyrrhiza glabra* L.) inhibit adhesion of *Helicobacter pylori* to human gastric mucosa. *J Ethnopharmacol*. 2009; 125 (2): 218-23.

[xxviii] Langmead et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. *Aliment Pharmacol Ther*. 2004; 19 (7): 739-47.

[xxix] Chen et al. Antagonistic activities of lactobacilli against *Helicobacter pylori* growth and infection in human gastric epithelial cells. *J Food Sci*. 2012; 77 (1): M9-14.

[xxx] Cellini , et al Inhibition of *Helicobacter pylori* by garlic extract (*Allium sativum*). *FEMS Immunol Med Microbiol*. 1996; 13: 273-77.

[xxxi] Tabak M et al. Cinnamon extracts' inhibitory effect on *Helicobacter pylori*. *J Ethnopharmacol*. 1999; 67 (3): 269-77.